Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Laquinimod
- The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
- The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
- The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
- Orphan Drug Designation granted for laquinimod for the treatment of Huntington's disease by the US Food and Drug Administration (FDA)
ANYARA
- Project proceeding according to plan
Tasquinimod, paquinimod and SILC
- Out-licensing activities are continuing
- The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
- Orphan Drug Designation granted for tasquinimod for the treatment of multiple myeloma by the US Food and Drug Administration (FDA)
- Product patent for SILC substances granted by the European Patent Office
Financial summary
| SEK M | Jan.-Mar. | Full-year | ||
| 2017 | 2016 | 2016 | ||
| Net sales | 4.7 | 3.9 | 19.0 | |
| Operating loss | -14.6 | -16.1 | -55.1 | |
| Loss after tax | -15.8 | -16.8 | -59.6 | |
| Loss per share, before and after dilution (SEK) | -0.16 | -0.19 | -0.65 | |
| Cash and cash equivalents (at close of period) | 62.7 | 76.5 | 77.7 | |
- Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017
For further information, please contact:
| Tomas Leanderson, President and CEO Tel: +46 (0) 46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 |
The report is also available at www.activebiotech.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/e19e9aad-c392-4cf4-b127-da952a463a0f
